Worried about saying the wrong thing when talking about neurodiversity? This guide breaks down the basics: what to say, what ...

One of the vaccines for a specific strain of an avian virus could come from a research lab on the campus of South Dakota ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

In the subset of patients whose tumors expressed PD-L1 (combined positive score [CPS] ≥10), median progression-free survival (PFS ... heterozygosity (LOH)-low subgroup of participants who ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in ...